174 related articles for article (PubMed ID: 16283539)
21. Patrick Couvreur: inspiring pharmaceutical innovation.
Stanwix H
Nanomedicine (Lond); 2014 May; 9(6):759-61. PubMed ID: 24981648
[TBL] [Abstract][Full Text] [Related]
22. Towards a more rational regulation of the development of new medicines. Report of a European workshop held in Sestri Levante, Italy, September 28-30, 1976.
Eur J Clin Pharmacol; 1977 Mar; 11(3):233-8. PubMed ID: 852499
[No Abstract] [Full Text] [Related]
23. The pharmaceutical sciences in 2020--report of a conference organized by the Board of Pharmaceutical Sciences of the International Pharmaceutical Federation (FIP).
Shah VP; Besançon LJ; Stolk P; Tucker G; Crommelin DJ
Eur J Pharm Sci; 2009 Dec; 38(5):419-25. PubMed ID: 19651208
[TBL] [Abstract][Full Text] [Related]
24. Extra-label drug use--pharmaceutical industry view.
Welser JR
J Am Vet Med Assoc; 1993 May; 202(10):1635-42;discussion 1654-8. PubMed ID: 8514571
[No Abstract] [Full Text] [Related]
25. Patent protection in Europe of pharmaceuticals found to have a further medical indication.
Cockbain J
Pharm Pat Anal; 2012 Mar; 1(1):17-8. PubMed ID: 24236708
[No Abstract] [Full Text] [Related]
26. Workshop/conference report on EMA draft guideline on validation of bioanalytical methods.
Blume H; Brendel E; Brudny-Klöppel M; Grebe S; Lausecker B; Rohde G; Siethoff C
Eur J Pharm Sci; 2011 Feb; 42(3):300-5. PubMed ID: 21185936
[TBL] [Abstract][Full Text] [Related]
27. Nanomedicines: The magic bullets reaching their target?
Flühmann B; Ntai I; Borchard G; Simoens S; Mühlebach S
Eur J Pharm Sci; 2019 Feb; 128():73-80. PubMed ID: 30465818
[TBL] [Abstract][Full Text] [Related]
28. [Are children getting the right drugs?].
Flaten O
Tidsskr Nor Laegeforen; 2006 Feb; 126(4):481; author reply 481. PubMed ID: 16477299
[No Abstract] [Full Text] [Related]
29. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
Buckley LA; Dorato MA
Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
[TBL] [Abstract][Full Text] [Related]
30. Minimum acceptable requirements for introduction and marketing of drugs.
Lasagna L
Drugs; 1974; 7(6):409-13. PubMed ID: 4422210
[No Abstract] [Full Text] [Related]
31. The drug regulatory system of the United States Food and Drug Administration: a defense of current requirements for safety and efficacy.
Simmons HE
Int J Health Serv; 1974; 4(1):95-107. PubMed ID: 4829901
[No Abstract] [Full Text] [Related]
32. Overview of genotoxic impurities in pharmaceutical development.
Bercu JP; Dobo KL; Gocke E; McGovern TJ
Int J Toxicol; 2009; 28(6):468-78. PubMed ID: 19966139
[TBL] [Abstract][Full Text] [Related]
33. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
[TBL] [Abstract][Full Text] [Related]
34. The draft FDA guideline on non-inferiority clinical trials: a critical review from European pharmaceutical industry statisticians.
Huitfeldt B; Hummel J;
Pharm Stat; 2011; 10(5):414-9. PubMed ID: 21932294
[TBL] [Abstract][Full Text] [Related]
35. Tripartite meeting. Paediatric regulatory guidelines: do they help in optimizing dose selection for children?
Baber NS
Br J Clin Pharmacol; 2005 Jun; 59(6):660-2. PubMed ID: 15948928
[No Abstract] [Full Text] [Related]
36. Testing new drugs in naked apes and getting the dose right in their young.
Ritter JM
Br J Clin Pharmacol; 2010 Oct; 70(4):467-70. PubMed ID: 20840438
[No Abstract] [Full Text] [Related]
37. Systems validation for parenteral clinical drugs--application to R&D and QC laboratories.
Tetzlaff RF
J Parenter Sci Technol; 1983; 37(2):45-50. PubMed ID: 6345744
[No Abstract] [Full Text] [Related]
38. New safe medicines faster: A proposal for a key action within the European union's 6th framework programme.
Bjerrum OJ
Pharmacol Toxicol; 2000; 86 Suppl 1():23-6. PubMed ID: 10905750
[TBL] [Abstract][Full Text] [Related]
39. Overhauling oversight--European drug legislation.
Tsang L
Nat Biotechnol; 2005 Sep; 23(9):1050-3. PubMed ID: 16151389
[TBL] [Abstract][Full Text] [Related]
40. [Review of the development in European Legislation on the harmonisation of the laws for medicinal products].
Lehmann B
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):713-21. PubMed ID: 18584107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
